Potential repurposing of oncology drugs for the treatment of Alzheimer's disease

BMC Medicine

Wataru Araki¹ 

[1] Department of Demyelinating Disease and Aging, National Institute of Neuroscience, National Center of Neurology and Psychiatry, Kodaira, Tokyo 187-8502, Japan

关键词: drug repositioning;    disease-modifying drugs;    amyloid β-peptide;    Alzheimer's disease;   

Others  :  857127
DOI  :  10.1186/1741-7015-11-82

 received in 2013-02-12, accepted in 2013-03-26,  发布年份 2013

【 摘 要 】

Alzheimer's disease (AD) is the most common form of neurodegenerative dementia, affecting about 30 million people worldwide. Despite recent advances in understanding its molecular pathology, no mechanism-based drugs are currently available that can halt the progression of AD. Because amyloid-β-peptide (Aβ), a primary component of senile plaques, is thought to be a central pathogenic culprit, several disease-modifying therapies are being developed, including inhibitors of Aβ-producing proteases and immunotherapies with anti-Aβ antibodies. Drug repositioning or repurposing is regarded as a complementary and reasonable approach to identify new drug candidates for AD. This commentary will discuss the clinical relevance of an attractive candidate compound reported in a recent paper by Hayes et al. (BMC Medicine 2013) as well as perspectives regarding the possible repositioning of oncology drugs for the treatment of AD.

See related research article here http://www.biomedcentral.com/1741-7015/11/81 webcite

【 授权许可】

   
2013 Araki; licensee BioMed Central Ltd.

【 参考文献 】

• [1]Brookmeyer R, Johnson E, Ziegler-Graham K, Arrighi HM: Forecasting the global burden of Alzheimer's disease. Alzheimers Dement 2011, 7:61-73.
• [2]LaFerla FM, Oddo S: Alzheimer's disease: abeta, tau and synaptic dysfunction. Trends Mol Med 2005, 11:170-176.
• [3]Klafki HW, Staufenbiel M, Kornhuber J, Wiltfang J: Therapeutic approaches to Alzheimer's disease. Brain 2006, 129:2840-2855.
• [4]Hardy J, Selkoe DJ: The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics. Science 2002, 297:353-356.
• [5]Walsh DM, Selkoe DJ: A beta oligomers - a decade of discovery. J Neurochem 2007, 101:1172-1184.
• [6]De Strooper B, Vassar R, Golde T: The secretases: enzymes with therapeutic potential in Alzheimer disease. Nat Rev Neurol 2010, 6:99-107.
• [7]Salomone S, Caraci F, Leggio GM, Fedotova J, Drago F: New pharmacological strategies for treatment of Alzheimer's disease: focus on disease modifying drugs. Br J Clin Pharmacol 2012, 73:504-517.
• [8]Corbett A, Pickett J, Burns A, Corcoran J, Dunnett SB, Edison P, Hagan JJ, Holmes C, Jones E, Katona C, Kearns I, Kehoe P, Mudher A, Passmore A, Shepherd N, Walsh F, Ballard C: Drug repositioning for Alzheimer's disease. Nat Rev Drug Discov 2012, 11:833-846.
• [9]Appleby BS, Nacopoulos D, Milano N, Zhong K, Cummings JL: A review: treatment of Alzheimer's disease discovered in repurposed agents. Dement Geriatr Cogn Disord 2013, 35:1-22.
• [10]Hayes CD, Dey D, Palavicini JP, Wang H, Patkar KA, Minond D, Nefzi A, Lakshmana MK: Striking reduction of amyloid plaque burden in an Alzheimer's mouse model after chronic administration of carmustine. BMC Med, in press.
• [11]Roe CM, Behrens MI, Xiong C, Miller JP, Morris JC: Alzheimer disease and cancer. Neurology 2005, 64:895-898.
• [12]Driver JA, Beiser A, Au R, Kreger BE, Splansky GL, Kurth T, Kiel DP, Lu KP, Seshadri S, Wolf PA: Inverse association between cancer and Alzheimer's disease: results from the Framingham Heart Study. BMJ 2012, 344:e1442.
• [13]Caraci F, Battaglia G, Bruno V, Bosco P, Carbonaro V, Giuffrida ML, Drago F, Sortino MA, Nicoletti F, Copani A: TGF-β1 pathway as a new target for neuroprotection in Alzheimer's disease. CNS Neurosci Ther 2011, 17:237-249.
• [14]Rubio-Perez JM, Morillas-Ruiz JM: A review: inflammatory process in Alzheimer's disease, role of cytokines. ScientificWorldJournal 2012, 2012:756357.
• [15]Wyss-Coray T, Lin C, Yan F, Yu GQ, Rohde M, McConlogue L, Masliah E, Mucke L: TGF-β1 promotes microglial amyloid-β clearance and reduces plaque burden in transgenic mice. Nat Med 2001, 7:614-618.
• [16]Cramer PE, Cirrito JR, Wesson DW, Lee CY, Karlo JC, Zinn AE, Casali BT, Restivo JL, Goebel WD, James MJ, Brunden KR, Wilson DA, Landreth GE: ApoE-directed therapeutics rapidly clear β-amyloid and reverse deficits in AD mouse models. Science 2012, 335:1503-1506.
• [17]Tippmann F, Hundt J, Schneider A, Endres K, Fahrenholz F: Up-regulation of the alpha-secretase ADAM10 by retinoic acid receptors and acitretin. FASEB J 2009, 23:1643-1654.
• [18]Kawahara K, Nishi K, Suenobu M, Ohtsuka H, Maeda A, Nagatomo K, Kuniyasu A, Staufenbiel M, Nakagomi M, Shudo K, Nakayama H: Oral administration of synthetic retinoid Am80 (Tamibarotene) decreases brain beta-amyloid peptides in APP23 mice. Biol Pharm Bull 2009, 32:1307-1309.